BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Hu X, Mao C, Fan L, Luo H, Hu Z, Zhang S, Yang Z, Zheng H, Sun H, Fan Y, Yang J, Shi C, Xu Y. Modeling Parkinson's Disease Using Induced Pluripotent Stem Cells. Stem Cells Int 2020;2020:1061470. [PMID: 32256606 DOI: 10.1155/2020/1061470] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 4.5] [Reference Citation Analysis]
Number Citing Articles
1 Sen T, Thummer RP. CRISPR and iPSCs: Recent Developments and Future Perspectives in Neurodegenerative Disease Modelling, Research, and Therapeutics. Neurotox Res 2022. [PMID: 36044181 DOI: 10.1007/s12640-022-00564-w] [Reference Citation Analysis]
2 Arango D, Bittar A, Esmeral NP, Ocasión C, Muñoz-Camargo C, Cruz JC, Reyes LH, Bloch NI. Understanding the Potential of Genome Editing in Parkinson's Disease. Int J Mol Sci 2021;22:9241. [PMID: 34502143 DOI: 10.3390/ijms22179241] [Reference Citation Analysis]
3 Koszła O, Stępnicki P, Zięba A, Grudzińska A, Matosiuk D, Kaczor AA. Current Approaches and Tools Used in Drug Development against Parkinson's Disease. Biomolecules 2021;11:897. [PMID: 34208760 DOI: 10.3390/biom11060897] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
4 Cacabelos R, Carrera I, Martínez O, Alejo R, Fernández-Novoa L, Cacabelos P, Corzo L, Rodríguez S, Alcaraz M, Nebril L, Tellado I, Cacabelos N, Pego R, Naidoo V, Carril JC. Atremorine in Parkinson's disease: From dopaminergic neuroprotection to pharmacogenomics. Med Res Rev 2021;41:2841-86. [PMID: 34106485 DOI: 10.1002/med.21838] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
5 Schulz JM. The Potential of Induced Pluripotent Stem Cells to Treat and Model Alzheimer's Disease. Stem Cells Int 2021;2021:5511630. [PMID: 34122554 DOI: 10.1155/2021/5511630] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
6 Coccia E, Ahfeldt T. Towards physiologically relevant human pluripotent stem cell (hPSC) models of Parkinson's disease. Stem Cell Res Ther 2021;12:253. [PMID: 33926571 DOI: 10.1186/s13287-021-02326-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
7 Perrone F, Cacace R, van der Zee J, Van Broeckhoven C. Emerging genetic complexity and rare genetic variants in neurodegenerative brain diseases. Genome Med 2021;13:59. [PMID: 33853652 DOI: 10.1186/s13073-021-00878-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
8 Antonov SA, Novosadova EV. Current State-of-the-Art and Unresolved Problems in Using Human Induced Pluripotent Stem Cell-Derived Dopamine Neurons for Parkinson's Disease Drug Development. Int J Mol Sci 2021;22:3381. [PMID: 33806103 DOI: 10.3390/ijms22073381] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
9 Avazzadeh S, Baena JM, Keighron C, Feller-Sanchez Y, Quinlan LR. Modelling Parkinson's Disease: iPSCs towards Better Understanding of Human Pathology. Brain Sci 2021;11:373. [PMID: 33799491 DOI: 10.3390/brainsci11030373] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
10 Choi DK, Kim YK, HoonYu J, Min SH, Park SW. Genome editing of hPSCs: Recent progress in hPSC-based disease modeling for understanding disease mechanisms. Prog Mol Biol Transl Sci 2021;181:271-87. [PMID: 34127196 DOI: 10.1016/bs.pmbts.2021.01.020] [Reference Citation Analysis]
11 Behl T, Kaur G, Fratila O, Buhas C, Judea-Pusta CT, Negrut N, Bustea C, Bungau S. Cross-talks among GBA mutations, glucocerebrosidase, and α-synuclein in GBA-associated Parkinson's disease and their targeted therapeutic approaches: a comprehensive review. Transl Neurodegener 2021;10:4. [PMID: 33446243 DOI: 10.1186/s40035-020-00226-x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 19] [Article Influence: 16.0] [Reference Citation Analysis]
12 Gois Beghini D, Iwao Horita S, Cascabulho CM, Anastácio Alves L, Henriques-Pons A. Induced Pluripotent Stem Cells: Hope in the Treatment of Diseases, including Muscular Dystrophies. Int J Mol Sci 2020;21:E5467. [PMID: 32751747 DOI: 10.3390/ijms21155467] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]